|
End-of-day quote
Pakistan S.E.
22/10/2026
|
5-day change | 1st Jan Change | ||
| 310.22 PKR | -1.05% |
|
-0.52% | -20.41% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 1,26,403 | 1,24,132 | 98,795 | - | - |
| Change | - | -1.8% | -20.41% | - | - |
| Enterprise Value (EV) | 1,26,403 | 1,24,132 | 98,795 | 98,795 | 98,795 |
| Change | - | -1.8% | -20.41% | 0% | 0% |
| P/E | 19.3x | 12.4x | 9.34x | 7.76x | 6.92x |
| PBR | - | 3.69x | 2.59x | 2.2x | 1.91x |
| PEG | - | 0.2x | 1.7x | 0.4x | 0.6x |
| Capitalization / Revenue | - | 1.88x | 1.44x | 1.32x | 1.21x |
| EV / Revenue | - | 0x | 1.44x | 1.32x | 1.21x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.04 | 20.81 | 23 |
| Rate of return | - | 4.36% | 5.82% | 6.71% | 7.41% |
| EPS 2 | 20.52 | 31.48 | 33.21 | 39.96 | 44.85 |
| Distribution rate | - | 54% | 54.3% | 52.1% | 51.3% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 310.22 | 310.22 | 310.22 |
| Nbr of stocks (in thousands) | 3,18,467 | 3,18,467 | 3,18,467 | - | - |
| Announcement Date | 24/03/25 | 26/03/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.34x | - | - | 5.82% | 36Cr | |
| 37.7x | 13.43x | 28.51x | 0.52% | 1,16500Cr | |
| 39.17x | 6.59x | 18.54x | 1.99% | 64TCr | |
| 36.4x | 8.37x | 17.27x | 2.41% | 50TCr | |
| 20.97x | 5.15x | 12.78x | 2.55% | 38TCr | |
| 107.33x | 5.99x | 25.72x | 2.31% | 36TCr | |
| 21.95x | 5.71x | 14.04x | 2.79% | 30TCr | |
| 22.67x | 4.58x | 13.09x | 1.93% | 27TCr | |
| 28.38x | 7.14x | 12.79x | 2.26% | 24TCr | |
| -45.82x | 7.02x | 27.23x | 2.1% | 19TCr | |
| Average | 27.81x | 7.11x | 18.89x | 2.47% | 40.56TCr | |
| Weighted average by Cap. | 35.73x | 8.44x | 20.74x | 1.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
